Lineage Cell Therapeutics IncLCTX
Price$0.90

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $13.1M+37.7% YoYTTM through 30 Jun 2026
Net Income -$32.3MTTM through 30 Jun 2026
Free Cash Flow -$24.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin99.0%
EBITDA Margin-199.6%
Operating Margin-251.6%
Net Margin-246.6%

Returns

-146.6%ROE
-56.4%ROA

Balance Sheet Health

Debt / Equity0.06x
Current Ratio6.61x
Net Debt-$53.4Mnet cash position
Cash & Equivalents$37.4M

Quality Metrics

Altman Z-Score-3.00
Piotroski F-Score2 / 9
FCF Margin-186.4%
Rule of 40-149.3
Earnings-Beat Rate33.3%

Multi-Year Trend

Revenue
'15'20'21'22'23'24'25
FY2025: $14.6M
Diluted EPS-$0.19TTM
'15'16'17'22'23'24'25
FY2025: $-0.28

Dividend

No dividend

Capital Allocation

Capex Intensity4.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.